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Abstract 
Fibrogenesis represents the universal response of the liver to chronic liver injury. 
Complement factor C5 has been linked to fibrosis in murine toxic liver injury and human 
chronic hepatitis C. C5 may also play a central role in chronic cholestatic disorders, since the 
BA receptor FXR has been characterized as an activator of the C3 gene. We aimed to 
investigate, whether C5 deficiency is able to prevent biliary fibrosis in the mouse bile-duct-
ligation model. 
BDL for 1-4 weeks was performed in either Hc0/Hc0 mice (deficient for C5) or WT controls. 
BA levels were measured by RIA. Histological examination included H&E, sirius-red and 
immunohistochemistry. mRNA expression was quantified by RT-PCR. Protein expression 
levels were determined by Western blotting or ELISA. Enzymatic MMP-activity was analysed 
by zymography.  
One week BDL leads to fibrosis in WT (F2.0±0), while it is almost absent in Hc0/Hc0 mice 
(F0.5±0.5). No differences in fibrosis can be detected at week-4. Together with delayed 
fibrogenesis at week-1, fibrotic markers are decreased in Hc0/Hc0 mice. Expression of the 
inflammatory cytokine TNF-α is decreased in Hc0/Hc0 mice. In parallel C5 deficiency leads to 
an attenuated peribiliary infiltration of CD45+ cells in fibrotic areas together with decreased 
MMP-9 expression and gelatinase activity.  
The present study proves a functional role of C5 during biliary fibrogenesis. C5 deficiency 
leads to attenuated inflammation and normalized MMP-9 activity concomitantly with a 
significant reduction of fibrosis. C5 appears to be an attractive target for future therapeutic 
intervention in chronic cholestatic liver disease. 
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Abbreviations 
α-SMA: alpha-smooth muscle actin, BA: bile acid, BDL: bile duct ligation, Col: collagen, FXR: 
farnesoid X receptor, HE: Hematoxilin&Eosin, Ntcp: Na-dependent taurocholate transporter, 
MMP: matrix metalloproteinase, Mrp: multidrug resistance associated protein, PBC: primary 
biliary cirrhosis, PSC: primary sclerosing cholangitis, TGF: Transforming growth factor, TNF: 
tumor necrosis factor. 
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1. Introduction 
Cholestatic liver diseases account for a substantial subset of chronic liver disease in people 
and are among the leading indications for liver transplantation in all age-groups [1]. In 
adults, PBC, PSC and cholestatic forms of hepatitis frequently progress to cirrhosis and end-
stage-liver disease [2,3]. Without treatment, most patients eventually develop fibrosis and 
cirrhosis of the liver and may need liver transplantation in the late stage of disease [4]. 
Although of different etiology, the consequence of impaired bile flow in all cholestatic 
disorders is the retention of bile constituents including BAs. Although, recent advances have 
been made in the pathophysiological understanding of liver fibrogenesis [5], the 
development of effective therapies for chronic cholestatic disorders is still impaired by our 
insufficient knowledge of the molecular mechanisms by which cholestasis and retention of 
BAs injures the liver, and which fibrotic mechanism is involved. In chronic cholestatic 
disorders, T-lymphocytes and cytokines mediate persistent bile duct damage and biliary cells 
secrete fibrogenic mediators activating extracellular matrix formation by neighboring portal 
myofibroblasts [6,7]. In consequence, perisinusoidal hepatic stellate cells become activated 
and periportal fibrotic bands develop finally leading to end-stage cirrhosis. Irrespective of 
the well established cytoprotective and choleretic effects of the hydrophilic BA 
ursodeoxycholic acid (UDCA) no clear-cut benefit has been achieved with regard to disease 
progression and transplant-free survival in patients with PBC and PSC [8,9]. Recently, the 
side chain modified BA norUDCA has been shown to markedly improve biochemical and 
histological features in a mouse model of sclerosing cholangitis but clinical trials in humans 
are not available yet [10,11]. In the absence of an effective medical therapy, the delineation 
of further targets for intervention in cholestatic liver disease is urgently needed and 
represents the molecular basis for future treatment strategies. 
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It has been widely recognized that the complement system plays a critical role in the 
pathogenesis of a variety of chronic human disorders including chronic liver disease [12]. 
Activation of the complement system initiates a cascade resulting in the cleavage of the 
central molecule of the complement system, C3, which in turn leads to a downstream 
cleavage of C5. The resulting products C3a, C5a and other complement components are 
activators of distinct cell surface receptors translating risk signals into defined cellular 
responses [13]. 
More than two decades ago, it has been noticed that serum complement levels, particularly 
C3, are increased in patients with obstructive jaundice [14], PBC [15] and PSC [16]. More 
recent evidence suggests, that the increase of C3 in PBC patients is not due to the underlying 
disease entity but rather due to cholestasis in general [17]. Similar conclusions can be drawn 
from the description of a PSC patient with complete obstruction of the common bile duct 
whose serum complement C3 and C4 levels normalized upon surgical reconstitution of bile 
flow [18]. Intriguingly, long-term plasma exchange treatment of patients with PBC even 
improved liver function and decreased fibrosis marker procollagen III aminopeptide along 
with reduced C3 activation [19]. 
These clinical observations highlight the possibility of a functional link between cholestasis 
or BA retention and complement activation on one side, and cholestasis-induced 
complement activation and fibrosis progression on the other side. Indeed, regulation of 
complement C3 expression by the nuclear BA receptor FXR has recently been demonstrated 
for both human and rodent genes [20]. Given the role of the complement system in chronic 
toxic liver injury in mice or chronic viral hepatitis C infection in humans [21,22], and the fact 
that different forms of liver injury activate fibrogenesis in a disease-specific fashion [23], we 
aimed to investigate the particular role of BA-induced complement activation in biliary 
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fibrosis. Aim of this study was therefore to characterize the effects of C5-deficiency on 
fibrogenesis in the murine BDL model which exhibits similar structural alterations to those 
observed in chronic biliary obstruction in man. 
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2. Material and methods 
2.1. Animals 
8-week old C5-deficient (Hc0/Hc0) male mice (B10.D2-Hc0H2dH2-T18c/oSnJ) and age- and 
gender matched control animals (B10.D2-Hc1H2dH2-T18c/oSnJ) were purchased from 
Jackson Laboratory (Bar Harbor, Maine, USA) and kept under standard conditions. BDL or 
sham-laparatomy was performed in either C5-deficient mice (n=4, each group) or WT 
controls (n=5, each group) as described previously [24]. After 1 and 4 weeks the mice were 
sacrificed and liver tissue and blood samples were harvested. Paraffin-embedded sections 
from both time points were analyzed after HE and sirius-red staining for the degree of 
hepatic fibrosis. The staging was described previously [21]. Additionally liver fibrosis was 
assessed in all animals histologically by quantification of the sirius-red–positive area, using 
the Adobe Photoshop CS3 software. The animals received humane care and the study 
protocols were approved by the local Government’s Animal Care Committee (Nr. 2008162). 
2.2. mRNA isolation and real-time RT-PCR 
Total RNA was isolated from liver by using RNeasy Mini Kit (Qiagen, Valencia, CA) according to 
manufacturer’s instructions. mRNA was reverse-transcribed using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosytems, Mannheim, Germany). Expression was 
normalised against β-actin. Real-time-PCR was performed using ABI TaqMan probes on an 
Applied Biosystems 7900HT RT-PCR System. Taqman Probes: Ntcp: Mm00441421_m1, 
Mrp3: Mm00551550_m1, Mrp4: Mm01226381_m1, Col I: Mm00801666_g1, Col III: 
Mm01254476_m1, α-SMA: Mm00725412_s1, TGF-β: Mm03024053_m1, β6-Integrin: 
Mm00445326_m1, TNF-α: Mm99999068_m1, β-actin: 4352341E. 
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2.3. Western Blotting 
Similar amounts of serum proteins were separated by SDS-PAGE, transferred to PVDF 
membrane and probed with C3 antibody (Santa Cruz, sc-20137, USA). After incubation with 
species-specific HRP-conjugated secondary antibody (Dianova, Hamburg, Germany) immune 
complexes were detected using ECL-PLUS detection kit (GE-Healthcare, Freiburg, Germany). 
Densitometric quantification of Western blots was performed using Adobe Photoshop CS3. 
2.4. MMP-9 Elisa 
Tissue lysates were normalized for protein concentration and equal amounts were used for 
ELISA. Hepatic MMP-9 protein expression was quantified by ELISA according to the 
manufacturer’s instructions (R&D Systems, DY909). 
2.5. BA quantification 
Serum BAs were measured using BA RIA Kit (MP Biomedicals, Ilkirch, France) according to 
the manufacturer’s specifications. 
2.6. Gelatinase assay. 
Proteolytic activity of the recombinant MMP-9 mutants was shown by gelatin zymography as 
described before [25]. For gelatin zymography 1mg/mL gelatin was copolymerized in a 7.5% 
PAGE gel and 20µg protein of pooled liver lysates of each group was loaded. 
2.7. In situ zymography  
An unfixed liver tissue cryoslice of 3µm thickness was stained with 1µM DAPI-solution for 
3min and subsequently washed in MMP-buffer. The fluorescein conjugated DQ gelatin 
(Molecular Probes) was dissolved at 99°C in MMP-buffer containing 1% agarose. Using an 
applicator, a cover slip was coated on one side with the hot agarose buffer. After 30s cooling 
at room temperature the cover slip is mounted onto the tissue slice and surplus buffer was 
rolled out to one side. The object slides were incubated overnight at 37°C in a water 
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saturated atmosphere. MMP-buffer: 50mM TRIS pH7.4, 100mM NaCl, 1mM CaCl2, 50µM 
ZnCl2. 
2.8. Immunohistological analysis 
Immunohistology was performed as described before [26]. Antibodies used in this study: 
Primary antibodies were used at 2µg/ml and incubated on cryoslices over night at 4°C: 
Collagen I (Biodesign, T40777R), CD45 (BD, 550539), MMP-9 (R&D-Systems, AF909). 
Secondary antibodies: goat anti-rabbit IgG Alexa-488, goat anti-rat IgG Alexa-488, donkey 
anti-goat IgG Alexa-568 (Molecular probes, A11008, A11006, A11057). 
 2.9. Statistical analysis 
Statistical significance (P<0.05) between respective sham-controls and BDL treated mice was 
determined by Mann-Whitney U-test. Data represent the meanSEM. Analyses were 
performed with PASW Statistics 18.0.0, (Chicago, IL, USA) and GraphPad 5.01 (GraphPad 
Software Inc., CA, USA).  
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3. Results 
3.1. Complement Factor C3 is increased in WT animals compared to C5-deficient animals 
To monitor for BA retention and complement activation induced by obstructive cholestasis 
serum BA and serum C3 levels were measured. Compared to WT animals Hc0/Hc0-BDL 
animals represent a 194-fold, WT-BDL animals a 104-fold higher BA level, respectively (WT, 
1.47±0.44μmol/L, n=5; Hc0/Hc0, 1.44±0.41μmol/L n=5; Hc0/Hc0-BDL, 389.6±35.1μmol/L, n=4; 
WT-BDL, 153.3±40.0μmol/L, n=5) (fig.1A). The difference between BDL animals was 
significant (P<0.05). C3 concentration was determined by Western blotting followed by 
densitometric analysis. Both, Hc0/Hc0-BDL and WT-BDL animals showed an increased 
complement C3 protein level compared to respective sham-controls (Hc0/Hc0-BDL 406±27%, 
WT-BDL 333±33%, each P<0.05)(fig.1B,C).  
To confirm well established functional consequences of BA retention, we analyzed changes 
in the expression of BA transporters involved in the adaptation to BA overload. Basolateral 
Ntcp mRNA expression was significantly downregulated after 1-week of BDL in both strains 
(Hc0/Hc0 25.3±8.2% vs. WT 41.6±13.4%) (fig.1D). For the retrograde salvage transporter 
Mrp3, an mRNA induction in BDL mice could be observed for both Hc0/Hc0-BDL and WT-BDL 
compared to respective sham-controls (234.7±67.8% and 192±44.3%; P<0.05 each) (fig.1E). 
In parallel, Mrp4 mRNA expression was increased in BDL mice (Hc0/Hc0 812.1±264.4% and 
WT 231.3±25.6% of respective controls; P<0.05 each) (fig.1F). 
 
3.2. Decreased fibrosis in C5 deficient animals with BDL 
To determine whether fibrosis progression is different after BDL in Hc0/Hc0 compared to WT 
controls and sham-operated animals, respective tissue was analyzed microscopically. In 
Hc0/Hc0-BDL animals, sirius-red staining of paraffin-embedded tissue sections revealed a 
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lower stage of fibrosis (F 0.5±0.5 P<0.05) compared to WT-BDL animals (mean F 2.0±0). In 
figure 2A representative sections of controls and treated animals are shown, which clearly 
illustrate an absent peribiliary fibrosis which was observed in 3 out of 4 Hc0/Hc0 mice. In 
parallel a significant reduced sirius-red–positive area in histology in Hc0/Hc0-BDL compared 
to WT treated animals (111.5±46.5 vs. 316.8±110%, P<0.05) was measured (fig.2C). After 4 
weeks Hc0/Hc0-BDL animals show a histological degree of fibrosis comparable to their WT-
BDL counterparts (data not shown).  
 
3.3. Markers for fibrosis are elevated in WT animals, but not in C5-deficient animals 
To further evaluate these differences in fibrosis progression between WT and knock out 
animals at the molecular level, expression of a set of relevant fibrosis-related genes was 
analyzed at week 1. 
Lower levels of collagen I and III (0,26-fold and 0.15-fold of WT-BDL, respectively; P<0.05) 
parallel the decreased fibrosis in Hc0/Hc0-BDL mice. Alpha-smooth muscle actin (α-SMA) as a 
marker for activated hepatic stellate cells (HSC) was significantly increased in WT-BDL 
animals compared to Hc0/Hc0 mice (3.7-fold of Hc0/Hc0-BDL), which show an expression 
comparable to WT mice (123.7±50%). mRNA expression of the profibrotic TGF-β and β6-
Integrin (as part of αvβ6-Integrin) was reduced in Hc0/Hc0-BDL mice (0.57-fold and 0.06-fold 
of WT-BDL, respectively; P<0.05). In parallel to diminished profibrotic markers, the 
expression of proinflammatory cytokines is decreased in Hc0/Hc0-BDL mice (TNF-α 0.27-fold 
of WT-BDL) (fig.3). In line with these findings lower amounts of liver damage and infiltration 
of macrophages were observed in Hc0/Hc0-BDL mice observed in HE-staining (fig.2A). 
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3.4. Infiltration of leukocytes and concomitant MMP-9 increase in WT-BDL is absent in 
Hc0/Hc0-BDL 
To verify inflammatory changes and fibrosis-associated events caused by BDL in the 
respective tissue, immunohistochemistry of frozen sections stained with pan-leukocyte 
marker CD45, collagen I and MMP-9 were prepared. A prominent infiltration of CD45+ cells 
in fibrotic areas and an increased MMP-9 expression in WT-BDL animals could be monitored, 
while only marginal infiltration of leukocytes (CD45+) and only a minor induction of MMP-9 
could be observed in Hc0/Hc0-BDL mice (fig.4). In line with these immunohistochemical 
findings, MMP-9 ELISA revealed a significant quantitative increase of MMP-9 protein 
expression in BDL compared to untreated WT mice (166±19% of controls; P<0.05), while 
Hc0/Hc0-BDL showed an MMP-9 expression equivalent to all untreated or sham-operated 
control groups (90±17% of untreated WT controls) (fig.3B). To monitor the functional MMP-
activity, gelatinase zymography have been performed. Compared to WT-BDL, Hc0/Hc0-BDL 
showed a prominently decreased gelatinase activity (fig.3C). To finally localize this enzymatic 
activity, in-situ zymography determined an increased gelatinase activity around the fibrotic 
bile ducts in WT-BDL mice (fig.3D).  
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4. Discussion  
Common bile duct obstruction inevitably initiates the process of cholangiocyte proliferation 
and hepatic fibrogenesis ultimately leading to liver cirrhosis unless a reconstitution of bile 
flow can be facilitated either by surgery or drainage [27]. Evidence from a limited number of 
studies and individual observations, points to an activation of complement components, 
particularly C3, during obstructive cholestasis [14,17,18]. These former observations have 
been reproduced in a recent analysis of the biliary transcriptome in a mouse model of 
experimental biliary atresia where the overexpression of the C3a receptor and C1 is 
suggestive of the activation of the complement cascade during bile duct injury and 
obstruction [28]. An increased complement C3 protein level could be observed in our study 
in both, Hc0/Hc0-BDL and WT-BDL mice, which can be explained by the fact that C3 is located 
upstream to C5 in the complement activation cascade. This finding is well in accordance with 
the observed increase in serum BA levels. It has recently been shown that complement C3 
expression is inducible by BAs and their nuclear receptor FXR [20]. Furthermore, BA overload 
causes adaptive changes in hepatocellular transporter expression as observed by decreased 
basolateral Ntcp [24] and the induction of the retrograde basolateral salvage transporters 
Mrp3 and 4 [29] which can observed in our study.  
Experimental common BDL induces dynamic changes in mouse livers. In parallel to bile duct 
proliferation which is detectable starting from day 3 and continuously increasing until day 14 
after BDL, liver fibrosis visualized by sirius-red staining is increasing from day 5 until day 14 
without further deterioration thereafter [30]. In our study, bile duct-ligated wildtype mice 
develop fibrosis stage F2 at day 7 which is completely absent in 3 out of 4 C5-deficient mice 
(F0). This finding was confirmed by a reduced sirius-red–positive area in histology in Hc0/Hc0-
BDL mice compared to WT treated animals. However, the almost absence of fibrosis in these 
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animals is of transient nature, since histology after 4 weeks of BDL revealed similar fibrosis 
stages in both C5-deficient and WT animals. The significant delay of biliary fibrosis after 1 
week of BDL in C5-deficient mice was paralleled by reduced mRNA levels of fibrosis-
associated genes including collagen I and collagen III, the stellate cell activation marker α-
SMA, the profibrotic cytokine TGF-β, as well as β6-integrin, as part of the αvβ6-integrin [31]. 
Together with an increased mRNA expression of the proinflammatory cytokine TNF-α in WT-
BDL animals, an excess of infiltrating leukocytes was monitored around the fibrotic bile 
ducts. Additionally, an increase of MMP-9 expression during chronic biliary obstruction has 
been described in WT livers [30] which could also be detected in our study. The 
immunhistological colocalization of CD45+ cells and MMP-9 protein characterizes these 
infiltrating leukocytes as a source of MMP-9 expression. Both, CD45+ cells and MMP-9 
protein are clearly reduced in Hc0/Hc0-BDL compared to WT-BDL mice together with a 
decreased proteolytic gelatinase activity in the same area. Reduced peribiliary infiltration of 
leukocytes is consistent with a reduction of inflammatory cytokines as established activators 
of MMP-9 expression [32]. Decreased hepatic TNF-α mRNA expression in our study is well in 
accordance with the absent induction in MMP-9 expression in C5-deficient mice.  
Another recent study on C5a-receptor-deficient mice demonstrated a protection against 
ethanol induced liver damage in a complement- and macrophage-dependent, but toll like 
receptor-4 independent way [33]. A reduced TNF-α expression in C5a-receptor-deficient 
animals in this study confirms our findings. A similar decrease in MMP-9 with antifibrotic 
intervention in obstructive cholestasis has been observed in the past after application of 
liver growth factor [34] and captopril [35].  
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It becomes more and more evident that the complement system plays an important 
pathophysiological role in chronic liver disease irrespective of the underlying mechanism. 
After the first publication of C5 as a modifier of fibrosis in chronic toxic liver injury in mice 
and chronic viral hepatitis C infection in humans [21], several reports confirmed the 
pathophysiological impact of the complement system on viral hepatitis C [22], non-alcoholic 
fatty liver disease [36] and alcoholic liver disease [37]. Genetic studies in healthy subjects 
have demonstrated that C5 haplotype-tagging polymorphisms as common gene variants 
contribute to variations in the serum activity of the profibrogenic C5 [38]. The findings of our 
study hold the potential for future therapeutic intervention in patients with cholestatic liver 
disease without conventional treatment options. Small peptidic C5-receptor-1 antagonists 
have been successfully used in liver fibrosis-susceptible BALB/cJ mice to reduce hepatic 
collagen levels and the stage of fibrosis [21] and may be further investigated as an 
antifibrotic candidate drug in experimental cholestatic liver injury. As a potential option for 
future clinical application in liver disease, humanized anti-C5 antibodies (Eculizumab [39], 
Pexelizumab [40]) are available in the meantime. 
In summary, our study demonstrates that C5 plays a critical role in the development of 
biliary fibrosis. We show that C5 deficiency results in a significantly delayed fibrosis in BDL 
mice. A putative mechanism for this reduced fibrosis after 1-week BDL could be the reduced 
inflammation, seen as attenuated peribiliary infiltration of CD45+ cells in fibrotic areas, 
together with a decreased MMP-9 expression and gelatinase activity in Hc0/Hc0 mice.  
Taken together C5 appears to be an attractive target for future therapeutic intervention in 
chronic cholestatic liver disease.  
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FIGURE LEGENDS 
 
Fig.1: Serum BAs, serum complement C3 levels and BA transporter mRNA expression. 
(A) Serum BAs from WT, Hc0/Hc0, WT-BDL and Hc0/Hc0-BDL animals were measured by RIA. 
(B) Serum proteins were analysed by western blot (protein loading 25µg/lane, Coomasie gel 
as loading control). C. Densitometric analysis of serum C3 alpha chain. Relative protein 
expression was compared to WT. Relative mRNA quantification of BA transporters (D) Ntcp, 
(E) Mrp3 and (F) Mrp4. Asterisk represents P<0.05. 
  
Fig.2: Liver histology and stages of fibrosis in Hc0/Hc0-BDL. 
(A) Representative sirius-red stainings of liver sections from sham-control and BDL, of WT 
and Hc0/Hc0 animals and representative HE-stainings of liver sections from WT-BDL and 
Hc0/Hc0-BDL animals. Decreased histological fibrosis was observed in Hc0/Hc0-BDL as well as 
increased histological liver damage in HE-staining in WT-BDL animals (Figures show 
maximum of observed damages in both strains). Insert (magnification 100x) shows bile duct 
infarct in a higher magnification. A lower infiltration rate of immune cells was observed in 
Hc0/Hc0 animals. Scale bars: 200μm. Overlapping single pictures were taken (original 
magnification 50x) and remerge with Adobe Photoshop CS3 for overview. (B) Fibrosis. 
Asterisk represents P<0.05. (C) Sirius-red positive areas in %. Reduced fibrosis in Hc0/Hc0-BDL 
is confirmed by a significant decrease in sirius-red positive area compared to treated WT-
BDL animals. Asterisk represents P<0.01. 
 
Fig.3: Quantification fibrosis related genes and MMP-9 expression in WT-BDL and Hc0/Hc0-
BDL mice. 
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(A) RT-PCR of fibrosis related genes. Col I and Col III, α-SMA, β6-Integrin, profibrotic TGF-β 
and proinflammatory cytokine TNF-α were analyzed. (B) MMP-9 Protein quantification. (C) 
Zymography of randomized control and BDL animals. Semi-quantification enzymatic activity 
was performed by densitometric analysis. (D) In situ zymography demonstrates gelatinolytic 
activity (green fluorescence). Bile ducts were highlighted by a dashed line bar=25µm. All 
sections were labelled with DNA-specific fluorochrome DAPI. Asterisk represents P<0.05. 
 
Fig.4: Increased MMP-9 expression in WT animals and its absence in C5-deficient animals. 
Immunohistochemistry of WT-BDL and Hc0/Hc0-BDL mice demonstrated infiltration of MMP-
9 expressing leukocytes in fibrotic areas of WT mice after BDL treatment. Staining was 
performed with (A,B) MMP-9 and COLI and (C,D) MMP-9 and CD-45 antibodies, respectively. 
Merge of the pictures shows protein colocalisation. All sections were labelled with DNA-
specific fluorochrome DAPI. Scale bar: 25µm. 
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Highlights: 
 
> C3 is activated during biliary obstruction in both WT and C5-deficient mice. > C5 
significantly attenuates the amount of fibrosis in response upon BDL. > C5-deficient mice 
show decreased expression of fibrosis-associated genes and TNF-α. > Reduced peribiliary 
infiltration of leucocytes in fibrotic areas with C5 deficiency. > Decreased expression of 
MMP-9 and decreased gelatinase activity in C5-deficient mice. 
